Abstract:Receptor activator of nuclear factor-κB ligand (RANKL) is considered the principal regulator of osteoclast differentiation. Therefore, strategies interfering with the RANKL-RANK signaling pathway may effectively inhibit osteoclast differentiation and mitigate bone resorption. Consequently, RANKL has become a promising target for new drug design strategies. Despite extensive research on specific drugs and antibodies, only a few have shown efficacy in treating osteoporosis. To address this challenge, we aimed to explore new approaches for designing drugs for osteoporosis. In this study, a 3D quantitative structure-activity relationship (QSAR) pharmacophore model was built for RANKL with reference to known inhibitor IC50 values. The optimal pharmacophore model was then employed as a 3D query to screen databases for novel lead compounds. The obtained compounds were subjected to ADMET and TOPKAT analyses to predict drug pharmacokinetics and toxicity. Molecular docking and de novo evolution approaches were applied to verify the docking binding affinities of the compounds. Five candidate compounds were subjected to further in vitro analyses to assess their anti-osteoporotic effects, among which compound 4 demonstrated significant inhibitory activity, achieving an inhibitory rate of 92.6 % on osteoclastogenesis at a concentration of 10 μM. Subsequent molecular dynamics (MD) simulations to assess the stability and behavior of compound 4 and its evolved variant, ZINC00059014397_Evo, within the RANKL binding site revealed that the variant is a potential therapeutic agent for targeting osteoclasts. This study offers valuable insights for developing next generation RANKL inhibitors for osteoporosis treatments.

Identifying Marine-Derived Tanzawaic Acid Derivatives as Novel Inhibitors against Osteoclastogenesis and Osteoporosis via Downregulation of NF-κB and NFATc1 Activation

Isoalantolactone Inhibits RANKL-induced Osteoclast Formation Via Multiple Signaling Pathways

12-Deoxyphorbol 13-Acetate Inhibits RANKL-induced Osteoclastogenesis Via the Attenuation of MAPK Signaling and NFATc1 Activation

Discovery of New Inhibitors Against Both NF-κB and Osteoclastogenesis from In-House Library with Α, Β-Unsaturated-enone Fragment.

Tectorigenin inhibits RANKL-induced osteoclastogenesis via suppression of NF-κB signalling and decreases bone loss in ovariectomized C57BL/6.

Tatarinan N Inhibits Osteoclast Differentiation Through Attenuating NF-κB, MAPKs and Ca2+-dependent Signaling.

A Novel Diterpenoid Suppresses Osteoclastogenesis and Promotes Osteogenesis by Inhibiting Ifrd1-Mediated and IκBα-Mediated p65 Nuclear Translocation.

Synthesis and biological evaluation of heterocyclic ring-fused betulinic acid derivatives as novel inhibitors of osteoclast differentiation and bone resorption.

Novel heterocyclic ring-fused oleanolic acid derivatives as osteoclast inhibitors for osteoporosis

Tatarinan O, a Lignin-Like Compound from the Roots of Acorus Tatarinowii Schott Inhibits Osteoclast Differentiation Through Suppressing the Expression of C-Fos and NFATc1.

Discovery of a novel anti-osteoporotic agent from marine fungus-derived structurally diverse sirenins

Discovery of Novel Neo -Clerodane Derivatives as Potent Dual-Functional Antiosteoporosis Agents through Targeting Peroxisome Proliferator-Activated Receptor-γ

OA10 is a Novel P38alpha Mitogen-Activated Protein Kinase Inhibitor That Suppresses Osteoclast Differentiation and Bone Resorption.

Synthesis of Heterocyclic Ring-Fused Tricyclic Diterpene Analogs As Novel Inhibitors of Rankl-Induced Osteoclastogenesis and Bone Resorption

L‐tetrahydropalmatine Suppresses Osteoclastogenesis in Vivo and in Vitro Via Blocking RANK‐TRAF6 Interactions and Inhibiting NF‐κB and MAPK Pathways

Identification of novel RANKL inhibitors through in silico analysis

Tereticornate A suppresses RANKL-induced osteoclastogenesis via the downregulation of c-Src and TRAF6 and the inhibition of RANK signaling pathways

Synthesis and Biological Evaluation of Rhein Amides As Inhibitors of Osteoclast Differentiation and Bone Resorption

Briarane-type diterpenoids suppress osteoclastogenisis by regulation of Nrf2 and MAPK/NF-kB signaling pathway

OA-4 Inhibits Osteoclast Formation and Bone Resorption Via Suppressing RANKL Induced P38 Signaling Pathway

(S)-2-(cyclobutylamino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)isonicotinamide Attenuates RANKL-Induced Osteoclast Differentiation by Inhibiting NF-κB Nuclear Translocation